سعر جينيترا 10مجم 10 كبسولات 2026

Atomoxetine 10 mg hard capsules (10 capsules), a non-stimulant selective norepinephrine reuptake inhibitor used for attention-deficit/hyperactivity disorder (ADHD); marketed in Egypt by Genesis Pharmaceuticals.

• Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.Population: Adults and children 6 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in children and adolescents: nausea, vomiting, fatigue, decreased appetite, abdominal pain and somnolence.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Most common adverse reactions in adults: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction and urinary hesitation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to atomoxetine or other constituents of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Use with a monoamine oxidase inhibitor (MAOI) or within 2 weeks after stopping an MAOI.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Narrow-angle glaucoma.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: atomoxetine increases the risk of suicidal thinking in children and adolescents; closely monitor for suicidality, clinical worsening and unusual changes in behaviour.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe liver injury can occur; discontinue and do not restart in patients with jaundice or laboratory evidence of liver injury.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious cardiovascular events: sudden death, stroke and myocardial infarction have been reported; assess for cardiac disease before treatment. Atomoxetine can increase blood pressure and heart rate, which should be monitored.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Monoamine oxidase inhibitors (MAOIs)Contraindicated together or within 14 days of each other because of the risk of serious, sometimes fatal, reactions.DailyMed (U.S. National Library of Medicine)
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine)Increase atomoxetine exposure; titrate more slowly (start 0.5 mg/kg/day or 40 mg/day and increase only if symptoms fail to improve after 4 weeks).DailyMed (U.S. National Library of Medicine)
• Antihypertensive drugs and pressor agentsAtomoxetine may decrease the effectiveness of antihypertensives and potentiate pressor agents because of possible effects on blood pressure.DailyMed (U.S. National Library of Medicine)

• Available human data are insufficient to establish a drug-associated risk of major birth defects or miscarriage; some adverse developmental outcomes occurred in animal studies. A pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on the presence of atomoxetine in human milk or effects on the breastfed infant; atomoxetine is present in animal milk. Weigh the benefits of breastfeeding against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Atomoxetine: Thought to act through selective inhibition of the presynaptic norepinephrine transporter; the precise mechanism in ADHD is unknown (US Strattera label).